GPCR/G protein

All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
-
B5026 GR 46611Summary: 5-HT1D receptor agonist -
B5018 SB 203186 hydrochlorideSummary: Potent 5-HT4 receptor antagonist -
B5263 ZD 2079Summary: β3-adrenoceptor agonist -
B3536 Ramosetron HydrochlorideSummary: 5-HT3 receptor antagonist -
B5091 RS 100329 hydrochlorideSummary: Subtype-selective α1A-adrenoceptor antagonist -
B3494 Sarpogrelate hydrochloride1 CitationSummary: 5-HT2A receptor inhibitor -
B5023 Pronethalol hydrochlorideSummary: β-adrenergic antagonist -
B4795 Labetalol HClSummary: A mixed α-/β-adrenergic antagonist -
B3459 Dihydroergotamine mesylateSummary: An ergot derivative with agonistic activity for α-adrenergic, dopaminergic, and serotonergic receptors -
B2265 BRL-15572Summary: 5-HT1D receptor antagonist
